<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id>
<journal-title>Frontiers in Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">1664-302X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmicb.2016.02129</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Microbiology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>TRIM5&#x03B1; Promotes Ubiquitination of Rta from Epstein&#x2013;Barr Virus to Attenuate Lytic Progression</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Huang</surname> <given-names>Hsiang-Hung</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x2020;</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chen</surname> <given-names>Chien-Sin</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x2020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/389551/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname> <given-names>Wen-Hung</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hsu</surname> <given-names>Shih-Wei</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tsai</surname> <given-names>Hsiao-Han</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/398755/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname> <given-names>Shih-Tung</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Chang</surname> <given-names>Li-Kwan</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn001"><sup>&#x002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/383666/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Biochemical Science and Technology, College of Life Science, National Taiwan University</institution> <country>Taipei, Taiwan</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Internal Medicine, Kaohsiung Medical University Hospital</institution> <country>Kaohsiung, Taiwan</country></aff>
<aff id="aff3"><sup>3</sup><institution>Molecular Genetics Laboratory, Department of Microbiology and Immunology, Chang-Gung University</institution> <country>Taoyuan, Taiwan</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: <italic>Michael Nevels, University of St Andrews, UK</italic></p></fn>
<fn fn-type="edited-by"><p>Reviewed by: <italic>David J. Hughes, University of St Andrews, UK; Ayman S. El-Guindy, Yale University, USA</italic></p></fn>
<fn fn-type="corresp" id="fn001"><p>&#x002A;Correspondence: <italic>Li-Kwan Chang, <email>changlk@ntu.edu.tw</email></italic></p></fn>
<fn fn-type="other" id="fn002"><p><sup>&#x2020;</sup><italic>These authors have contributed equally to this work.</italic></p></fn>
<fn fn-type="other" id="fn003"><p>This article was submitted to Virology, a section of the journal Frontiers in Microbiology</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>05</day>
<month>01</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<volume>7</volume>
<elocation-id>2129</elocation-id>
<history>
<date date-type="received">
<day>11</day>
<month>10</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>12</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2017 Huang, Chen, Wang, Hsu, Tsai, Liu and Chang.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Huang, Chen, Wang, Hsu, Tsai, Liu and Chang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p>Replication and transcription activator (Rta), a key protein expressed by Epstein&#x2013;Barr virus (EBV) during the immediate-early stage of the lytic cycle, is responsible for the activation of viral lytic genes. In this study, GST-pulldown and coimmunoprecipitation assays showed that Rta interacts <italic>in vitro</italic> and <italic>in vivo</italic> with TRIM5&#x03B1;, a host factor known to be involved in the restriction of retroviral infections. Confocal microscopy results revealed that Rta colocalizes with TRIM5&#x03B1; in the nucleus during lytic progression. The interaction involves 190 amino acids in the N-terminal of Rta and the RING domain in TRIM5&#x03B1;, and it was further found that TRIM5&#x03B1; acts as an E3 ubiquitin ligase to promote Rta ubiquitination. Overexpression of TRIM5&#x03B1; reduced the transactivating capabilities of Rta, while reducing TRIM5&#x03B1; expression enhanced EBV lytic protein expression and DNA replication. Taken together, these results point to a critical role for TRIM5&#x03B1; in attenuating EBV lytic progression through the targeting of Rta for ubiquitination, and suggest that the restrictive capabilities of TRIM5&#x03B1; may go beyond retroviral infections.</p>
</abstract>
<kwd-group>
<kwd>TRIM5&#x03B1;</kwd>
<kwd>Rta</kwd>
<kwd>ubiquitination</kwd>
<kwd>Epstein&#x2013;Barr virus</kwd>
<kwd>viral&#x2013;host interactions</kwd>
</kwd-group>
<counts>
<fig-count count="7"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="46"/>
<page-count count="11"/>
<word-count count="0"/>
</counts>
</article-meta>
</front>
<body>
<sec><title>Introduction</title>
<p>Epstein&#x2013;Barr virus (EBV), a member of the human herpesvirus family, is an oncogenic virus that infects lymphoid and epithelial cells. Although EBV normally remains latent after infecting B lymphocyte cells, the virus must enter the lytic cycle to proliferate and produce infectious particles. The pivotal role of the two EBV intermediate-early proteins, Replication and transcription activator (Rta) and Zta, in activating the transcription of EBV lytic genes is well-documented (<xref ref-type="bibr" rid="B35">Speck et al., 1997</xref>; <xref ref-type="bibr" rid="B45">Zalani et al., 1997</xref>; <xref ref-type="bibr" rid="B23">Liu and Speck, 2003</xref>; <xref ref-type="bibr" rid="B1">Amon and Farrell, 2005</xref>). In previous studies, we showed that Rta is conjugated to SUMO-1 by Ubc9 and PIAS (protein inhibitor of activated STAT) proteins, and this sumoylation enhances Rta transactivation activity (<xref ref-type="bibr" rid="B10">Chang et al., 2004</xref>). Rta is also modified by SUMO-2 (<xref ref-type="bibr" rid="B18">Heilmann et al., 2010</xref>), and can be ubiquitinated via the SUMO chain by a SUMO-targeted E3 ubiquitin ligase, RNF4, thereby inhibiting EBV lytic activation (<xref ref-type="bibr" rid="B43">Yang et al., 2013</xref>).</p>
<p>In this study, we identified a second E3 ubiquitin ligase that promotes Rta ubiquitination to influence EBV lytic progression, TRIM5&#x03B1;. TRIM5&#x03B1; is a member of the tripartite motif (TRIM) protein superfamily, and acts as a host restriction factor that limits retroviral infection (<xref ref-type="bibr" rid="B36">Stremlau et al., 2004</xref>; <xref ref-type="bibr" rid="B27">Pertel et al., 2011</xref>). Earlier studies have shown that TRIM5&#x03B1; from rhesus macaques (rhTRIM5&#x03B1;) restricts early events in human immunodeficiency virus (HIV)-1 infection, while human TRIM5&#x03B1; restricts infection by N-tropic murine leukemia virus (N-MLV) (<xref ref-type="bibr" rid="B44">Yap et al., 2004</xref>). As an intrinsic immunity protein, TRIM5&#x03B1; catalyzes the synthesis of unanchored K63-linked polyubiquitin chains, and then activates NF-&#x03BA;B or AP-1 dependent transcription (<xref ref-type="bibr" rid="B27">Pertel et al., 2011</xref>). TRIM5&#x03B1; contains B boxes, a coiled-coil domain, and a RING domain, and can function as an E3 ubiquitin ligase (<xref ref-type="bibr" rid="B29">Reymond et al., 2001</xref>). In addition, TRIM5&#x03B1; contains a SPRY/B30.2 domain with two SUMO-interaction motifs (SIMs), which are required for N-MLV restriction (<xref ref-type="bibr" rid="B2">Arriagada et al., 2011</xref>). This SPRY/B30.2 domain can also directly bind with the HIV capsid, and is believed to be critical for HIV restriction (<xref ref-type="bibr" rid="B31">Sawyer et al., 2005</xref>; <xref ref-type="bibr" rid="B37">Stremlau et al., 2005</xref>; <xref ref-type="bibr" rid="B24">Luban, 2007</xref>; <xref ref-type="bibr" rid="B16">Ganser-Pornillos et al., 2011</xref>). Moreover, TRIM5&#x03B1;-mediated ubiquitin conjugation is required for HIV-1 capsid destabilization and inhibition of reverse transcription (<xref ref-type="bibr" rid="B7">Campbell et al., 2016</xref>). Interestingly, SIM mutations in TRIM5&#x03B1; not only lead to loss of restriction capability against N-MLV (<xref ref-type="bibr" rid="B2">Arriagada et al., 2011</xref>), but the mutations also prevent TRIM5&#x03B1; from shuttling into the cell nucleus, thus rendering it unable to restrict incoming HIV retrovirion cores (<xref ref-type="bibr" rid="B4">Brandariz-Nunez et al., 2013</xref>).</p>
<p>Although TRIM5&#x03B1; primarily acts to limit the propagation of retroviruses (<xref ref-type="bibr" rid="B17">Hatziioannou et al., 2004</xref>; <xref ref-type="bibr" rid="B21">Keckesova et al., 2004</xref>; <xref ref-type="bibr" rid="B26">Perron et al., 2004</xref>; <xref ref-type="bibr" rid="B36">Stremlau et al., 2004</xref>; <xref ref-type="bibr" rid="B44">Yap et al., 2004</xref>), it has been reported that rhTRIM5&#x03B1; can hamper the replication of herpes simplex virus (HSV) (<xref ref-type="bibr" rid="B28">Reszka et al., 2010</xref>), a double-stranded DNA virus. In this study, we identified an interaction between TRIM5&#x03B1; and the EBV viral protein, Rta, using GST-pulldown and coimmunoprecipitation assays. TRIM5&#x03B1; and Rta colocalized in the nucleus, and we further found that TRIM5&#x03B1; can act as an E3 ubiquitin ligase that promotes Rta ubiquitination. This subsequently leads to the downregulation of Rta transactivation capabilities, indicating that TRIM5&#x03B1; may play a critical role in attenuating EBV lytic progression. These results suggest that the restrictive abilities of TRIM5&#x03B1; are not limited to retroviruses, and may have interesting implications for antiviral research and development.</p>
</sec>
<sec id="s1" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec><title>Cell Lines and EBV Lytic Induction</title>
<p>P3HR1, a Burkitt&#x2019;s lymphoma cell line latently infected by EBV (<xref ref-type="bibr" rid="B3">Ben-Bassat et al., 1976</xref>), was cultured in RPMI1640 medium containing 10% fetal calf serum. 293T cells were cultured in Dulbecco&#x2019;s modified Eagle&#x2019;s medium (DMEM) containing 10% fetal calf serum. P3HR1 cells were treated with 30 ng/mL 12-<italic>O</italic>-tetradecanoylphorbol-13-acetate (TPA) and 3 mM sodium butyrate to activate the EBV lytic cycle (<xref ref-type="bibr" rid="B25">Luka et al., 1979</xref>; <xref ref-type="bibr" rid="B14">Davies et al., 1991</xref>; <xref ref-type="bibr" rid="B11">Chang and Liu, 2000</xref>).</p>
</sec>
<sec><title>Plasmids</title>
<p>Plasmids pGEX-TRIM5&#x03B1; and pEGFP-TRIM5&#x03B1; were constructed by inserting a DNA fragment, which was amplified by PCR using pLPCX-TRIM5&#x03B1; as a template (NIH AIDS reagent program, USA) and the primers TRIM5&#x03B1;-F (5&#x2032;-CCGGAATTCATGGCTTCTGGAATCCTGGT) and TRIM5&#x03B1;-R (5&#x2032;-ACGCGTCGACTCAAGAGCTTGGTGAGCACA), into the <italic>Eco</italic>RI and <italic>Sal</italic>I sites in pGEX-4T1 (Amersham) and pEGFP-C2 (Clontech), respectively. DNA fragments, which encode the regions in TRIM5&#x03B1; from amino acids 1 to 261, 81 to 493, and 261 to 493 were amplified by PCR. These DNA fragments were then inserted into the <italic>Eco</italic>RI and <italic>Sal</italic>I sites in pEGFP-C2 to generate pEGFP-TRIM5&#x03B1;-dC, pEGFP-TRIM5&#x03B1;-dN, and pEGFP-TRIM5&#x03B1;-dNM, respectively. The DNA fragment from amino acids 1 to 261 was also inserted into pTag2B to create pFlag-TRIM5&#x03B1;-dC. Plasmids that express deletion mutants of GFP-Rta, including GFP-N190, GFP-N191/415, and GFP-Rev have been described previously (<xref ref-type="bibr" rid="B20">Hsu et al., 2005</xref>; <xref ref-type="bibr" rid="B8">Chang et al., 2010</xref>; <xref ref-type="bibr" rid="B42">Yang and Chang, 2013</xref>). Plasmids pFlag-Ub, pFlag-Rta, and pET-Rta, which express Flag-tagged ubiquitin, Flag-tagged Rta and His-tagged Rta, were described earlier (<xref ref-type="bibr" rid="B43">Yang et al., 2013</xref>). For transient transfection assays, the reporter plasmid, pBMRF1, was constructed by inserting a PCR-amplified DNA fragment containing the -172 to +20 region in BMRF1 into pGL2-Basic (<xref ref-type="bibr" rid="B8">Chang et al., 2010</xref>). Plasmid pBMLF1-RRE containing the RRE sequence from the BMLF1 promoter and a TATA sequence was synthesized and inserted into pGL2-Basic (<xref ref-type="bibr" rid="B10">Chang et al., 2004</xref>). Similarly, the RRE sequence from the BMRF1 promoter and a TATA sequence was synthesized and inserted into pGL2-Basic to generate pBMRF1-RRE.</p>
</sec>
<sec><title>MALDI-TOF Mass Spectrometry</title>
<p>P3HR1 cells were treated with TPA and sodium butyrate for 24 h to activate the EBV lytic cycle and Rta expression. Cells were harvested by low speed centrifugation and lysed using mRIPA buffer (50 mM Tris-HCl (pH 7.8), 150 mM NaCl, 5 mM EDTA, 0.5% Triton X-100, 0.5% Nonidet P-40), and proteins in the lysate were immunoprecipitated using anti-Rta antibody and protein A/G-agarose beads (Millipore). The beads were washed with mRIPA buffer for three times, and proteins on the beads were then extracted with electrophoresis sample buffer (10% glycerol, 60 mM Tris-HCl pH 6.8, 2% SDS, 2.5% &#x03B2;-mercaptoethanol, 2 mM EDTA) and subjected to 2-D polyacrylamide gel electrophoresis. Proteins in the gel were stained with Coomassie blue, and prospective protein spots in the gel were then excised. The proteins in the spots were digested with trypsin according to an in-gel digestion protocol (<xref ref-type="bibr" rid="B33">Shevchenko et al., 1996</xref>), and the resulting peptides were analyzed using a Bruker Biflex III MALDI-TOF mass spectrometer (Bruker Daltonics) (<xref ref-type="bibr" rid="B40">Wu et al., 2007</xref>). The m/z ratios of the digested peptides and their fragmented ions were used to search the annotated human genome in the Mass Spectrometry protein sequence Database (MSDB), using Mascot search software v1.8 (Matrix Science Inc). The search criteria used were as follows: maximum of one missed trypsin cleavage; variable modification, including carbamidomethylation; and 1 Da peptide mass tolerance. Only proteins identified as significant hits (<italic>p</italic> &#x003C; 0.05) by Mascot peptide mass fingerprint search were selected.</p>
</sec>
<sec><title>Protein Expression and GST Pulldown Assay</title>
<p><italic>Escherichia coli</italic> BL21(DE3)(pGEX-TRIM5&#x03B1;) and <italic>E. coli</italic> BL21(DE3)(pGST) were cultured to the mid-log phase and then treated with 0.1 mM isopropyl &#x03B2;-<sc><sc><sc>D</sc></sc></sc>-1-thiogalactopyranoside (IPTG) to, respectively, induce the expression of GST-TRIM5&#x03B1; and GST according to a method described earlier (<xref ref-type="bibr" rid="B10">Chang et al., 2004</xref>). GST and GST-TRIM5&#x03B1; were purified from bacterial lysates using glutathione-Sepharose 4B beads (GE healthcare).</p>
</sec>
<sec><title>Transient Transfection and Luciferase Assay</title>
<p>293T cells were transfected with plasmids using Turbofect (Thermo Fisher Scientific), according to the method recommended by the manufacturer. At 24&#x2013;48 h after transfection, cells were harvested and lysed using mRIPA lysis buffer [50 mM Tris-HCl (pH 7.8), 150 mM NaCl, 5 mM EDTA, 0.5% Triton X-100, 0.5% Nonidet P-40]. Luciferase assays were performed according to a method described earlier (<xref ref-type="bibr" rid="B12">Chang et al., 1998</xref>).</p>
</sec>
<sec><title>Coimmunoprecipitation of Rta and TRIM5&#x03B1;</title>
<p>293T cells were transfected with pCMV-Rta and pHA-TRIM5&#x03B1;, and at 24 h after transfection, cells were collected and lysed in mRIPA buffer. Proteins in the lysate were immunoprecipitated with anti-Rta and anti-HA antibodies. Protein A/G-agarose beads were then added to the lysate, and proteins bound to the beads were subsequently analyzed by immunoblotting. To detect ubiquitinated proteins, 293T cells were cotransfected with pCMV-R, pTag-2B, and pLPCX-TRIM5&#x03B1;. At 24 h after transfection, cells were treated with 5 &#x03BC;M MG132 for additional 12 h. Cells were harvested according to a method described earlier (<xref ref-type="bibr" rid="B10">Chang et al., 2004</xref>; <xref ref-type="bibr" rid="B43">Yang et al., 2013</xref>) to detect ubiquitin-conjugated proteins.</p>
</sec>
<sec><title>Immunoblot Analysis</title>
<p>Proteins were separated in SDS-polyacrylamide gels and then electrotransferred to Hybond C membranes (GE) at 90 V for 1 h, according to a method described elsewhere (<xref ref-type="bibr" rid="B10">Chang et al., 2004</xref>). The membrane was then probed with the appropriate antibodies, including anti-Rta (Argene), anti-TRIM5&#x03B1; (Santa Cruz), anti-HA (Roche), anti-GFP (Santa Cruz), anti-GST (Santa Cruz), anti-VCA (Argene), anti-BFRF3 (<xref ref-type="bibr" rid="B39">Wang et al., 2015</xref>), and anti-&#x03B1;-tubulin (Sigma) antibodies.</p>
</sec>
<sec><title>Immunofluorescence Analysis</title>
<p>P3HR1 cells were treated with sodium butyrate and TPA for 24 h, harvested by centrifugation, plated on poly-<sc><sc><sc>L</sc></sc></sc>-lysine (Sigma)-coated coverslips, and fixed with 4% paraformaldehyde in PBS for 30 min. Immunostaining was conducted using anti-Rta monoclonal antibodies (Argene) and anti-TRIM5&#x03B1; polyclonal antibodies (Santa Cruz). Cells were then treated with Alexa Fluor<sup>&#x00AE;</sup> 594 goat anti-mouse and Alexa Fluor<sup>&#x00AE;</sup> 488 goat anti-rabbit antibodies (Invitrogen). Nuclei were visualized by staining with 5 mg/mL 4&#x2032;-6-diamidino-2-phenylindole (DAPI). Cells were observed under a confocal laser scanning microscope (Leica TCS SP8).</p>
</sec>
<sec><title>Knockdown of TRIM5&#x03B1; Expression</title>
<p>TRIM5&#x03B1; shRNA and plasmids, including pMD2.G, pCMVDR8.91, and pLKO-shRNA, were purchased from the National RNAi Core Facility, Genomic Research Center, Academia Sinica, Taipei, Taiwan. 293T cells (2 &#x00D7; 10<sup>5</sup>) were cotransfected with plasmids expressing TRIM5&#x03B1; shRNA (target sequence: 5&#x2032;-CCAGACATTTGTGAATTTCAA-3&#x2032;; 2.25 &#x03BC;g), helper plasmids pMD2.G (0.25 &#x03BC;g) and pCMVDR8.91 (2.25 &#x03BC;g), using Turbofect <italic>in vitro</italic> transfection reagent (Thermo Fisher Scientific). Culture media was changed on the following day, and after an additional 24 h, viral supernatants were collected and filtered (0.22 &#x03BC;M), then stored at -80&#x00B0;C. Plasmid pLKO-shRNA was used as a negative control. For lentivirus infection, P3HR1 cells (3 &#x00D7; 10<sup>5</sup>/mL) were transduced with the generated lentiviruses, together with 5 &#x03BC;g/mL of polybrene. Infected P3HR1 cells were selected using 2 &#x03BC;g/mL puromycin in culture medium to produce stable cell lines according to the protocol<sup><xref ref-type="fn" rid="fn01">1</xref></sup>.</p>
</sec>
<sec><title>Determining Copy Numbers of EBV DNA</title>
<p>P3HR1 cells were treated with TPA and sodium butyrate to induce the lytic cycle. After 5 days of culturing, virus particles released into the medium were collected by ultracentrifugation at 25,000 &#x00D7; <italic>g</italic> for 2.5 h. EBV copy numbers were determined according to a method described previously (<xref ref-type="bibr" rid="B30">Ryan et al., 2004</xref>; <xref ref-type="bibr" rid="B13">Chiu et al., 2007</xref>). A standard curve was established using maxi-EBV DNA purified from <italic>E. coli</italic> after qPCR analysis. The amounts of EBV DNA purified from the virus in the culture medium were similarly analyzed and compared with the standard curve.</p>
</sec>
</sec>
<sec><title>Results</title>
<sec><title>Identification of Cellular Proteins Interacting with Rta</title>
<p>We treated P3HR1 cells with TPA and sodium butyrate for 24 h to activate the EBV lytic cycle and allowed the expression of Rta. Proteins interacting with Rta were then coimmunoprecipitated from cell lysates, using anti-Rta antibodies. A similar immunoprecipitation experiment was conducted using anti-IgG antibody as a control. Afterward, 2-D polyacrylamide gel electrophoresis of the immunoprecipitated proteins from each experiment (<bold>Figure <xref ref-type="fig" rid="F1">1A</xref></bold>) was conducted, and the gels were then stained with Coomassie blue and compared. The comparison results revealed 14 protein spots that appeared in the gel containing anti-Rta immunoprecipitated proteins, but not in the control gel (<bold>Figure <xref ref-type="fig" rid="F1">1A</xref></bold>). After digesting the proteins in these spots with trypsin, the resulting peptides were analyzed by MALDI-TOF mass spectrometry. The results revealed that five protein spots had peptide fingerprints matching those in the MSDB database (<bold>Figure <xref ref-type="fig" rid="F1">1B</xref></bold>). Among these, Spot D21 had a protein with a fingerprint matching that of TRIM5&#x03B1; (<bold>Figure <xref ref-type="fig" rid="F1">1C</xref></bold>), a known E3 ubiquitin ligase that promotes protein ubiquitination. Since Rta is known to be modified by ubiquitin (<xref ref-type="bibr" rid="B43">Yang et al., 2013</xref>), this study further sought to investigate whether TRIM5&#x03B1; influences the ubiquitination status and functions of Rta.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption><p><bold>MALDI-TOF mass spectrometry analysis of proteins that interact with Rta. (A)</bold> P3HR1 cells were treated with TPA and sodium butyrate for 24 h to induce the EBV lytic cycle and Rta expression. Cells were then lysed, and proteins in the lysate were immunoprecipitated (IP) with anti-Rta or anti-IgG antibodies. Immunoprecipitated proteins were denatured and analyzed by 2-D polyacrylamide gel electrophoresis. <bold>(B)</bold> Proteins in prospective spots were digested with trypsin and analyzed by MALDI-TOF mass spectrometry. Proteins with peptide fingerprints matching those in the MSDB database are listed in the table at right. <bold>(C)</bold> Peptide sequences in TRIM5&#x03B1; matching those in the D21 proteins are underlined.</p></caption>
<graphic xlink:href="fmicb-07-02129-g001.tif"/>
</fig>
</sec>
<sec><title>Rta Interacts with TRIM5&#x03B1; <italic>In vitro</italic> and <italic>In vivo</italic></title>
<p>To verify the interaction between Rta and TRIM5&#x03B1;, we expressed GST-TRIM5&#x03B1; and GST in <italic>E. coli</italic>, and bound these proteins to glutathione-Sepharose beads. GST-TRIM5&#x03B1;-glutathione-Sepharose beads were then added to <italic>E. coli</italic> BL21(DE3)(pET-Rta) lysates, and proteins pulled down by the beads were detected by immunoblotting with anti-Rta antibody. The results revealed that GST-TRIM5&#x03B1;, but not GST-glutathione-Sepharose beads, pulled down Rta (<bold>Figure <xref ref-type="fig" rid="F2">2A</xref></bold>, lanes 4 and 5), providing <italic>in vitro</italic> evidence of a direct interaction between TRIM5&#x03B1; and Rta. A coimmunoprecipitation experiment using lysates from 293T cells that had been cotransfected with pCMV-Rta and pLPCX-HA-TRIM5&#x03B1; similarly showed that anti-TRIM5&#x03B1; antibody immunoprecipitated HA-TRIM5&#x03B1; and coimmunoprecipitated Rta (<bold>Figure <xref ref-type="fig" rid="F2">2B</xref></bold>, lanes 4 and 8), while anti-Rta antibody immunoprecipitated Rta and coimmunoprecipitated HA-TRIM5&#x03B1; (<bold>Figure <xref ref-type="fig" rid="F2">2B</xref></bold>, lanes 3 and 7).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption><p><bold>Interaction between Rta and TRIM5&#x03B1;. (A)</bold> In a GST-pulldown assay, His-Rta (lanes 3&#x2013;5) was mixed with GST- (lane 4) and GST-TRIM5&#x03B1;- (lane 5) glutathione-Sepharose beads. Proteins pulled down by the beads were analyzed by immunoblotting (IB) with anti-Rta antibody. Proteins on the glutathione-Sepharose beads (lanes 1 and 2) and Rta in 1% of the lysate (lane 5) were also detected by immunoblotting. <bold>(B)</bold> Coimmunoprecipitation assay results. Anti-Rta and anti-TRIM5&#x03B1; antibodies were added to the lysate from 293T cells that had been transfected with pLPCX-HA-TRIM5&#x03B1; and pCMV-Rta. Lanes 1 and 5 were loaded with 3% of the cell lysate. Proteins immunoprecipitated (IP) with anti-Rta and anti-TRIM5&#x03B1; antibodies or anti-IgG antibody were detected by immunoblotting (IB), using anti-HA (lanes 1&#x2013;4) and anti-Rta antibodies (lanes 5&#x2013;8).</p></caption>
<graphic xlink:href="fmicb-07-02129-g002.tif"/>
</fig>
</sec>
<sec><title>Colocalization of TRIM5&#x03B1; with Rta in the Nucleus</title>
<p>The localization of Rta and TRIM5&#x03B1; in P3HR1 cells treated with TPA and sodium butyrate for 24 h was examined by indirect immunofluorescence. Under a confocal laser scanning microscope, we found that both Rta and TRIM5&#x03B1; formed speckles, many of which colocalized in the cell nucleus (<bold>Figures <xref ref-type="fig" rid="F3">3f&#x2013;j</xref></bold>). However, Rta was not observed if the cells were not treated with TPA and sodium butyrate (<bold>Figures <xref ref-type="fig" rid="F3">3a&#x2013;e</xref></bold>). P3HR1 cells treated with or without TPA and sodium butyrate were also stained with secondary antibodies as a control to demonstrate the specificity of anti-TRIM5&#x03B1; antibody (<bold>Figures <xref ref-type="fig" rid="F3">3k&#x2013;t</xref></bold>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption><p><bold>Subcellular localization of Rta and TRIM5&#x03B1;.</bold> P3HR1 cells were treated with sodium butyrate and TPA (SB/TPA) or DMSO (NC) for 24 h. Cells were incubated with monoclonal anti-Rta antibody <bold>(c,h)</bold> and polyclonal anti-TRIM5&#x03B1; antibody <bold>(b,g)</bold>. Cells were also stained with secondary antibodies <bold>(k&#x2013;t)</bold> as a control. Nuclei were visualized by DAPI staining <bold>(a,f)</bold>. Cells were observed under a confocal laser-scanning microscope, and <bold>(d,e,i,j,n,o,s,t)</bold> are merged images. Scale bar indicates 10 &#x03BC;m.</p></caption>
<graphic xlink:href="fmicb-07-02129-g003.tif"/>
</fig>
</sec>
<sec><title>Analysis of Interacting Domains in Rta and TRIM5&#x03B1;</title>
<p>We cotransfected 293T cells with pFlag-TRIM5&#x03B1; and plasmids expressing different segments of Rta that were fused to GFP (<bold>Figure <xref ref-type="fig" rid="F4">4A</xref></bold>). Control cells were cotransfected with plasmids expressing GFP and Flag-TRIM5&#x03B1;. Immunoblotting with anti-GFP antibody revealed that GFP and the GFP-Rta fusion proteins were expressed at similar levels after transfection (<bold>Figure <xref ref-type="fig" rid="F4">4B</xref></bold>, lanes 1&#x2013;5). Following immunoprecipitation with anti-Flag antibody, precipitated proteins were analyzed by immunoblotting with anti-GFP antibody. Results showed that GFP-N190 (<bold>Figure <xref ref-type="fig" rid="F4">4B</xref></bold>, lane 8), which contains 190 amino acids from the N-terminal of Rta, was coimmunoprecipitated with Flag-TRIM5&#x03B1;, indicating that this is the region in Rta that interacts with TRIM5&#x03B1;. In addition, we also observed a weak binding effect between TRIM5&#x03B1; and GFP-N191-415 (<bold>Figure <xref ref-type="fig" rid="F4">4B</xref></bold>, lane 9). However, GFP-Rev was not coimmunoprecipitated by Flag-TRIM5&#x03B1; (<bold>Figure <xref ref-type="fig" rid="F4">4B</xref></bold>, lane 10). A control experiment showed that Flag-TRIM5&#x03B1; was not coimmunoprecipitated with GFP (<bold>Figure <xref ref-type="fig" rid="F4">4B</xref></bold>, lane 6). These results were reproduced from at least three independent experiments. To identify the region in TRIM5&#x03B1; that interacts with Rta, we generated plasmids expressing GFP fused to different segments of TRIM5&#x03B1; (<bold>Figure <xref ref-type="fig" rid="F4">4C</xref></bold>). Following cotransfection of these plasmids with pFlag-Rta to 293T cells, cells were subsequently lysed, and the lysates subjected to immunoprecipitation using anti-Flag antibody (<bold>Figure <xref ref-type="fig" rid="F4">4D</xref></bold>, lanes 1&#x2013;5). Immunoblot analysis with anti-GFP antibody revealed that only GFP-TRIM5&#x03B1; and GFP-TRIM5&#x03B1;-dC were coimmunoprecipitated with Flag-Rta (<bold>Figure <xref ref-type="fig" rid="F4">4D</xref></bold>, lanes 7 and 10). In addition, 293T cells were cotransfected with plasmids encoding GFP-N190 and Flag-TRIM5&#x03B1;-dC, and immunoblot analysis revealed that GFP-N190 in cell lysates (<bold>Figure <xref ref-type="fig" rid="F4">4E</xref></bold>, lane 3) was immunoprecipitated by anti-Flag antibody (<bold>Figure <xref ref-type="fig" rid="F4">4E</xref></bold>, lane 3). However, control cells that were cotransfected with plasmids expressing GFP and Flag-TRIM5&#x03B1;-dC revealed that GFP was not coimmunoprecipitated with Flag-TRIM5&#x03B1;-dC (<bold>Figure <xref ref-type="fig" rid="F4">4E</xref></bold>, lane 2). These results indicate that the N-terminal of Rta interacts with the N-terminal RING domain in TRIM5&#x03B1;.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption><p><bold>Mapping the interaction domains in Rta and TRIM5&#x03B1;. (A)</bold> Plasmids that expressed GFP fused to different segments of Rta were used to delineate the region in Rta that interacts with TRIM5&#x03B1;. <bold>(B)</bold> 293T cells were cotransfected with pFlag-TRIM5&#x03B1; and plasmids expressing GFP or GFP-Rta fusion proteins (pEGFP-Rta, pEGFP-N190, pEGFP-N191-415, pEGFP-Rev, or pEGFP-C1). Input lanes were loaded with 5% of the lysate (lanes 1&#x2013;5). Proteins in the lysates were coimmunoprecipitated (IP) with anti-Flag antibody and analyzed by immunoblotting (IB) using anti-GFP antibody (lanes 6&#x2013;10). <bold>(C)</bold> Plasmids expressing various GFP-TRIM5&#x03B1; fusion proteins (GFP-TRIM5&#x03B1;, GFP-TRIM5&#x03B1;-dN, GFP-TRIM5&#x03B1;-dNM, GFP-TRIM5&#x03B1;-dC) were generated. <bold>(D)</bold> 293T cells were cotransfected with plasmids encoding GFP or GFP-TRIM5&#x03B1; fusion proteins (GFP-TRIM5&#x03B1;, GFP-TRIM5&#x03B1;-dN, GFP-TRIM5&#x03B1;-dNM, GFP-TRIM5&#x03B1;-dC). Input lanes were loaded with 5% of the lysate, and GFP-fusion protein expression levels were detected using anti-GFP antibody (lanes 1&#x2013;5). Proteins in the lysates were coimmunoprecipitated with anti-Flag antibody and analyzed by immunoblotting using anti-GFP antibody (lanes 6&#x2013;10). <bold>(E)</bold> 293T cells were cotransfected with pFlag-TRIM5&#x03B1;-dC and plasmids expressing either GFP-N190 or GFP. Input lanes were loaded with 5% of the lysate. Proteins in the lysates were coimmunoprecipitated with anti-Flag antibody and analyzed by immunoblotting using anti-GFP antibody.</p></caption>
<graphic xlink:href="fmicb-07-02129-g004.tif"/>
</fig>
</sec>
<sec><title>TRIM5&#x03B1; Promotes Rta Ubiquitination</title>
<p>TRIM5&#x03B1; has previously been shown to be an E3 ubiquitin ligase (<xref ref-type="bibr" rid="B41">Yamauchi et al., 2008</xref>), and the observation of Rta-TRIM5&#x03B1; interaction prompted us to investigate whether TRIM5&#x03B1; can influence Rta ubiquitination. We proceeded to transfect 293T cells with pCMV-Rta alone, or with pCMV-Rta and pFlag-Ub. At 24 h after transfection, cells were treated with MG132, a proteasome inhibitor, to prevent the degradation of Rta. When proteins from the lysates of cells transfected with pCMV-Rta alone were immunoprecipitated using anti-Flag antibody and assessed by immunoblotting with anti-Rta, a single non-specific band of about 95 kDa was detected (<bold>Figure <xref ref-type="fig" rid="F5">5A</xref></bold>, lane 1), which was also observed in previous studies (<xref ref-type="bibr" rid="B10">Chang et al., 2004</xref>; <xref ref-type="bibr" rid="B43">Yang et al., 2013</xref>). In 293T cells cotransfected with pCMV-Rta and pFlag-Ub, low amounts of ubiquitinated Rta were detected after the proteins in the lysates were immunoprecipitated with anti-Flag antibody and assessed by immunoblotting with anti-Rta antibody (<bold>Figure <xref ref-type="fig" rid="F5">5A</xref></bold>, lane 2). When cells were cotransfected with pCMV-Rta, pFlag-Ub, and 0.3 or 0.6 &#x03BC;g of pLCPX-TRIM5&#x03B1;, ubiquitinated Rta became more prominent (<bold>Figure <xref ref-type="fig" rid="F5">5A</xref></bold>, lanes 3 and 4), demonstrating that TRIM5&#x03B1; promotes Rta ubiquitination. Subsequently, 293T cells were transfected with TRIM5&#x03B1; shRNA to determine whether this would reduce Rta ubiquitination. In a control experiment, immunoblotting did not detect ubiquitinated Rta in cells that were transfected with pHA-Ub (<bold>Figure <xref ref-type="fig" rid="F5">5B</xref></bold>, lane 1). Ubiquitinated Rta was also detected in cells that were cotransfected with pFlag-Rta and pHA-Ub (<bold>Figure <xref ref-type="fig" rid="F5">5B</xref></bold>, lane 2). However, introducing TRIM5&#x03B1; shRNA reduced the amounts of ubiquitinated Rta (<bold>Figure <xref ref-type="fig" rid="F5">5B</xref></bold>, lanes 3 and 4).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption><p><bold>Enhancement of Rta ubiquitination by TRIM5&#x03B1;. (A)</bold> 293T cells were cotransfected with plasmids expressing Rta, Flag-ubiquitin, and TRIM5&#x03B1;. Proteins in the lysates were immunoprecipitated (IP) using anti-Flag antibody and assessed by immunoblotting (IB) with anti-Rta antibody. <bold>(B)</bold> 293T cells were cotransfected with plasmids pFlag-Rta, pHA-Ub, and pLKO-shTRIM5&#x03B1;, which encoded Flag-Rta, HA-ubiquitin and shTRIM5&#x03B1;, respectively. Proteins in the lysates were immunoprecipitated (IP) using anti-Flag antibody and analyzed by immunoblotting (IB) with anti-HA antibody. At 24 h after transfection, cells were treated with 5 &#x03BC;M MG132 for additional 12 h to inhibit proteasome degradation. The asterisk indicates a non-specific band, also detected in previous studies (<xref ref-type="bibr" rid="B10">Chang et al., 2004</xref>; <xref ref-type="bibr" rid="B43">Yang et al., 2013</xref>). Ub-Rta, ubiquitinated Rta.</p></caption>
<graphic xlink:href="fmicb-07-02129-g005.tif"/>
</fig>
</sec>
<sec><title>Influence of TRIM5&#x03B1; on Rta Transactivation Activity</title>
<p>It is known that Rta acts as a key immediate-early protein that transactivates viral lytic genes to move EBV into the lytic cycle. Therefore, we sought to evaluate the impact of enhanced TRIM5&#x03B1; expression and Rta ubiquitination on the transactivation capabilities of Rta. In a transient transfection assay, we examined how TRIM5&#x03B1; expression can influence Rta transactivation of the EBV BMRF1 promoter, using a luciferase reporter plasmid, pBMRF1 (<xref ref-type="bibr" rid="B10">Chang et al., 2004</xref>). After cotransfecting 293T cells with pCMV-Rta and pBMRF1, Rta transactivation of BMRF1 was measured by luciferase activity, and the values were taken as 100% (<bold>Figure <xref ref-type="fig" rid="F6">6A</xref></bold>). We further included 0.1&#x2013;0.4 &#x03BC;g of pLPCX-TRIM5&#x03B1; in cotransfections, and found that enhanced expression of TRIM5&#x03B1; gradually reduced BMRF1 promoter activation in a dose-dependent manner to just 37&#x2013;80% (<bold>Figure <xref ref-type="fig" rid="F6">6A</xref></bold>). A similar experiment also showed that cotransfection of pLPCX-TRIM5&#x03B1; similarly disrupted the ability of Rta to transactivate the BMRF1-RRE (<bold>Figure <xref ref-type="fig" rid="F6">6B</xref></bold>) and BMLF1-RRE (<bold>Figure <xref ref-type="fig" rid="F6">6C</xref></bold>) promoters, which contain Rta-responsive elements (RREs). These results show that overexpression of TRIM5&#x03B1; decreases Rta transactivation capability.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption><p><bold>Reduction of Rta transactivation activity by TRIM5&#x03B1;.</bold> 293T cells were cotransfected with pCMV-R, pLPCX-TRIM5&#x03B1;, and <bold>(A)</bold> pBMRF1, <bold>(B)</bold> pBMRF1-RRE, or <bold>(C)</bold> pBMLF1-RRE. Luciferase activities were assessed 24 h after transfection. Each transfection experiment was performed three times, and each sample in the experiment was prepared in duplicate. Rta, TRIM5&#x03B1;, and &#x03B1;-tubulin expressed by the cells were examined by immunoblotting (IB). The data obtained from the reporter assay were subjected to one-way analysis of variance (ANOVA) using SPSS software 12.0. <italic>P</italic>-values of &#x003C;0.05 were considered statistically significant. RLU, relative light units.</p></caption>
<graphic xlink:href="fmicb-07-02129-g006.tif"/>
</fig>
</sec>
<sec><title>Influence of TRIM5&#x03B1; on the Expression of EBV Lytic Proteins and Virion Production</title>
<p>P3HR1 cells were infected with lentivirus expressing TRIM5&#x03B1; shRNA or control shRNA, and cells were then treated with TPA and sodium butyrate to activate the EBV lytic cycle. We found that, compared with cells infected with control shRNA, infection by lentivirus expressing TRIM5&#x03B1; shRNA caused cells to express less TRIM5&#x03B1;, but more Rta and EA-D (<bold>Figure <xref ref-type="fig" rid="F7">7A</xref></bold>). The expression of TRIM5&#x03B1; shRNA also led to increases in the expression of two EBV capsid proteins, VCA and BFRF3 (<bold>Figure <xref ref-type="fig" rid="F7">7B</xref></bold>). Quantitative PCR results showed that after lytic activation of P3HR1 cells infected with lentivirus expressing control shRNA, viral yield was estimated at 3 &#x00D7; 10<sup>5</sup> EBV particles. However, for cells infected with lentivirus expressing TRIM5&#x03B1; shRNA, viral yields increased 400% to 1.2 &#x00D7; 10<sup>6</sup> viral particles (<bold>Figure <xref ref-type="fig" rid="F7">7C</xref></bold>). These results showed that TRIM5&#x03B1; expression serves to attenuate EBV lytic development.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption><p><bold>Influence of TRIM5&#x03B1; on EBV lytic progression. (A)</bold> P3HR1 cells were infected by lentivirus expressing TRIM5&#x03B1; shRNA (shTRIM5&#x03B1;) or control shRNA (Ct-shRNA). Thereafter, cells were treated with sodium butyrate and TPA (SB/TPA) for 48 h, and proteins in the lysates were examined by immunoblotting with anti-Rta, anti-EA-D, anti-TRIM5&#x03B1;, and anti-&#x03B1;-tubulin antibodies. <bold>(B)</bold> Cells were lysed at 120 h after TPA and sodium butyrate treatment, and the expression of VCA, BFRF3, and &#x03B1;-tubulin was examined by immunoblotting. <bold>(C)</bold> An EBV lytic DNA replication assay was conducted by qPCR to determine the copy numbers of EBV DNA. The amount of EBV DNA was determined by standard curve, which was in turn established using maxi-EBV DNA purified from <italic>E. coli</italic> after qPCR analysis. The data were subjected to one-way analysis of variance (ANOVA) using SPSS software 12.0. <italic>P</italic>-values of &#x003C;0.05 were considered statistically significant.</p></caption>
<graphic xlink:href="fmicb-07-02129-g007.tif"/>
</fig>
</sec>
</sec>
<sec><title>Discussion</title>
<p>Rta is a key immediate-early viral protein that is responsible for activating the transcription of EBV lytic genes, thereby triggering the viral lytic cascade (<xref ref-type="bibr" rid="B23">Liu and Speck, 2003</xref>; <xref ref-type="bibr" rid="B1">Amon and Farrell, 2005</xref>; <xref ref-type="bibr" rid="B20">Hsu et al., 2005</xref>). In this study, we utilized MALDI-TOF mass spectrometry to identify host proteins that can interact with Rta and affect Rta activation of the EBV lytic cycle. From the mass spectrometry results, we identified TRIM5&#x03B1; as an Rta-interacting protein (<bold>Figure <xref ref-type="fig" rid="F1">1</xref></bold>). Considering that TRIM5&#x03B1; is a known E3 ubiquitin ligase (<xref ref-type="bibr" rid="B41">Yamauchi et al., 2008</xref>), while Rta ubiquitination has also been reported to affect its transactivation capabilities (<xref ref-type="bibr" rid="B43">Yang et al., 2013</xref>), we therefore sought to confirm whether TRIM5&#x03B1; influences Rta ubiquitination, and if so, whether Rta transactivation ability is affected as a result. Our results also suggest that TRIM5&#x03B1; may be abundantly present in P3HR1 cells, as levels of TRIM5&#x03B1; were detectable by Coomassie blue staining of a 2-D polyacrylamide gel. Our previous studies identified cellular Rta-interacting proteins, such as MCAF1 and ATF2 (<xref ref-type="bibr" rid="B9">Chang et al., 2005</xref>; <xref ref-type="bibr" rid="B22">Lin et al., 2014</xref>), which were not detected by MALDI-TOF mass spectrometry analysis. It is likely that the amounts of these proteins binding to Rta are less than that of TRIM5&#x03B1;, causing the proteins to escape detection. In order to validate the interaction between Rta and TRIM5&#x03B1;, we conducted a GST-pulldown assay, and showed that GST-TRIM5&#x03B1;-glutathione-Sepharose beads pulled down His-Rta (<bold>Figure <xref ref-type="fig" rid="F2">2A</xref></bold>, lane 5) via the N-terminal region in Rta and the N-terminal RING domain in TRIM5&#x03B1; (<bold>Figure <xref ref-type="fig" rid="F4">4</xref></bold>). Conversely, anti-Rta antibody was also shown to coimmunoprecipitate HA-TRIM5&#x03B1; (<bold>Figure <xref ref-type="fig" rid="F2">2B</xref></bold>, lanes 3 and 8). Confocal microscopy results revealed that Rta colocalizes with TRIM5&#x03B1; in the nuclei of P3HR1 cells after EBV lytic induction (<bold>Figure <xref ref-type="fig" rid="F3">3</xref></bold>). Taken together, these results corroborate the mass spectrometry findings, and provide supporting evidence for Rta-TRIM5&#x03B1; interaction. Interestingly, previous studies have shown that TRIM5&#x03B1; primarily resides in the cytoplasm, so as to defend against incoming retroviral virions (<xref ref-type="bibr" rid="B36">Stremlau et al., 2004</xref>). We also examined the subcellular localization of GFP-TRIM5&#x03B1; and TRIM5&#x03B1; in 293T cells, and found that TRIM5&#x03B1; formed dots in the cytoplasm (data not shown). However, our findings suggest that the majority of TRIM5&#x03B1; is present in the nuclei of P3HR1 cells, rather than the cytoplasm (<bold>Figure <xref ref-type="fig" rid="F3">3</xref></bold>). Whether this is an anomaly that exists only in P3HR1 or lymphocyte cells, or a response to activation of the viral lytic cycle by previously latent EBV in the cell nuclei remains to be determined. It has been reported that TRIM5&#x03B1; can shuttle between the cytoplasm and nucleus in a manner that is dependent on amino acids 60&#x2013;93 in the N-terminal of TRIM5&#x03B1;, although there is no significant influence to the antiviral activity (<xref ref-type="bibr" rid="B15">Diaz-Griffero et al., 2011</xref>). Still, the factors driving TRIM5&#x03B1; shuttling have not been identified as yet, and it is possible that TRIM5&#x03B1; may relocate in response to different viral insults, via mechanisms that remain to be elucidated.</p>
<p>TRIM5&#x03B1; is known to act as an E3 ubiquitin ligase, and here we found that TRIM5&#x03B1; can promote Rta ubiquitination (<bold>Figure <xref ref-type="fig" rid="F5">5A</xref></bold>). Introducing TRIM5&#x03B1; shRNA inhibits the levels of ubiquitinated Rta in 293T cells (<bold>Figure <xref ref-type="fig" rid="F5">5B</xref></bold>). However, we were unable to detect the difference in the amounts of ubiquitinated Rta before and after the knockdown of TRIM5&#x03B1; in P3HR1 cells. EBV is known to express at least three deubiquitinases, including BSLF1, BPLF1, and BXLF1 (<xref ref-type="bibr" rid="B32">Schlieker et al., 2005</xref>; <xref ref-type="bibr" rid="B34">Sompallae et al., 2008</xref>). This may stabilize Rta, making the detection of its ubiquitination in P3HR1 cells more difficult. We also found that USP11, a deubiquitinase that acts against RNF4 activity (<xref ref-type="bibr" rid="B19">Hendriks et al., 2015</xref>), removes the ubiquitin chains on Rta efficiently (Chen et. al., unpublished results), suggesting that the ubiquitination of Rta is tightly regulated under physiological conditions. Additionally, overexpression of TRIM5&#x03B1; appears to hamper Rta transactivation of the EBV lytic cycle, as intracellular amounts of Rta, EA-D, BFRF3, and VCA viral lytic proteins in P3HR1 cells treated with sodium butyrate and TPA decreased with TRIM5&#x03B1; overexpression; moreover, expression of TRIM5&#x03B1; reduced the number of EBV virions produced by P3HR1 cells (<bold>Figure <xref ref-type="fig" rid="F7">7</xref></bold>). In a transient transfection study, we showed that the ability of Rta to transactivate three EBV lytic promoters is negatively affected in a dose-dependent manner by enhanced expression of TRIM5&#x03B1; (<bold>Figure <xref ref-type="fig" rid="F6">6</xref></bold>). Furthermore, the expression of TRIM5&#x03B1; shRNA significantly increased the number of EBV viral particles produced by P3HR1 cells treated with sodium butyrate and TPA (<bold>Figure <xref ref-type="fig" rid="F7">7</xref></bold>). These results show that TRIM5&#x03B1; expression attenuates Rta ability to activate the transcription of EBV lytic genes and promote EBV lytic development, and suggests that the antiviral properties of TRIM5&#x03B1; may extend beyond retroviruses.</p>
<p>So far, only a few proteins, including NK-&#x03BA;B and hTERT, are known to decrease the lytic potential of EBV (<xref ref-type="bibr" rid="B6">Cahir-McFarland et al., 2000</xref>; <xref ref-type="bibr" rid="B38">Terrin et al., 2007</xref>). Among these two proteins, NK-&#x03BA;B is known to inhibit EBV lytic transcription and replication (<xref ref-type="bibr" rid="B5">Brown et al., 2003</xref>), while hTERT disrupts the EBV lytic cycle via a mechanism that is as yet unclear (<xref ref-type="bibr" rid="B38">Terrin et al., 2007</xref>). Our previous research indicated that RNF4 can target SUMO-2-Rta to enhance the ubiquitination of Rta, thereby inhibiting EBV lytic progression (<xref ref-type="bibr" rid="B43">Yang et al., 2013</xref>). Here, we report another cellular protein, TRIM5&#x03B1;, which also can play a negative role in hampering EBV lytic development. It is known that Rta is constitutively expressed, particularly in epithelial cells (<xref ref-type="bibr" rid="B46">Zalani et al., 1992</xref>). The presence of TRIM5&#x03B1; may reduce Rta expression levels at this stage and allow the virus to be maintained in latency. Further research into the role of TRIM5&#x03B1; and its ability to influence EBV and other viral physiology may be warranted.</p>
<p>In summary, we demonstrate that an E3 ubiquitin ligase, TRIM5&#x03B1;, can interact in the cell nucleus with the EBV immediate-early protein, Rta. TRIM5&#x03B1; promotes Rta ubiquitination, and this subsequently disrupts Rta ability to transactivate EBV lytic genes. Overexpression of TRIM5&#x03B1; was found to reduce viral promoter activation and viral lytic gene expression in a dose-dependent manner. Moreover, TRIM5&#x03B1; reduced EBV virion production in P3HR1 cells treated with sodium butyrate and TPA to induce EBV lytic activation, while the application of TRIM5&#x03B1; shRNA significantly increased the production of EBV viral particles. Taken together, these results indicate that TRIM5&#x03B1; can hamper Rta transactivation via the promotion of Rta ubiquitination, and suggest that the antiviral properties of TRIM5&#x03B1; may not be limited to retroviruses.</p>
</sec>
<sec><title>Author Contributions</title>
<p>C-SC, S-TL, and L-KC designed the study; H-HH, C-SC, W-HW, S-WH and H-HT conceived and performed the experiments; H-HH and C-SC conducted statistical analysis; H-HH, C-SC, S-TL and L-KC wrote the manuscript.</p>
</sec>
<sec><title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer DJH and handling Editor declared their shared affiliation, and the handling Editor states that the process nevertheless met the standards of a fair and objective review.</p>
</sec>
</body>
<back>
<ack>
<p>This study was supported by the National Health Research Institute (Grant No. NHRI-EX105-10325BI) and the Ministry of Science and Technology, Taiwan (Grant No. 104-2311-B-002-015 and 104-2320-B-182-034-MY2).</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amon</surname> <given-names>W.</given-names></name> <name><surname>Farrell</surname> <given-names>P. J.</given-names></name></person-group> (<year>2005</year>). <article-title>Reactivation of Epstein-Barr virus from latency.</article-title> <source><italic>Rev. Med. Virol.</italic></source> <volume>15</volume> <fpage>149</fpage>&#x2013;<lpage>156</lpage>. <pub-id pub-id-type="doi">10.1002/rmv.456</pub-id></citation></ref>
<ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arriagada</surname> <given-names>G.</given-names></name> <name><surname>Muntean</surname> <given-names>L. N.</given-names></name> <name><surname>Goff</surname> <given-names>S. P.</given-names></name></person-group> (<year>2011</year>). <article-title>SUMO-interacting motifs of human TRIM5alpha are important for antiviral activity.</article-title> <source><italic>PLoS Pathog.</italic></source> <volume>7</volume>:<issue>e1002019</issue>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1002019</pub-id></citation></ref>
<ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ben-Bassat</surname> <given-names>H.</given-names></name> <name><surname>Goldblum</surname> <given-names>N.</given-names></name> <name><surname>Mitrani</surname> <given-names>S.</given-names></name> <name><surname>Klein</surname> <given-names>G.</given-names></name> <name><surname>Johansson</surname> <given-names>B.</given-names></name></person-group> (<year>1976</year>). <article-title>Concanavalin a receptors on the surface membrane of lymphocytes from patients with African Burkitt&#x2019;s lymphoma and lymphoma cell lines.</article-title> <source><italic>Int. J. Cancer</italic></source> <volume>17</volume> <fpage>448</fpage>&#x2013;<lpage>454</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.2910170406</pub-id></citation></ref>
<ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brandariz-Nunez</surname> <given-names>A.</given-names></name> <name><surname>Roa</surname> <given-names>A.</given-names></name> <name><surname>Valle-Casuso</surname> <given-names>J. C.</given-names></name> <name><surname>Biris</surname> <given-names>N.</given-names></name> <name><surname>Ivanov</surname> <given-names>D.</given-names></name> <name><surname>Diaz-Griffero</surname> <given-names>F.</given-names></name></person-group> (<year>2013</year>). <article-title>Contribution of SUMO-interacting motifs and SUMOylation to the antiretroviral properties of TRIM5alpha.</article-title> <source><italic>Virology</italic></source> <volume>435</volume> <fpage>463</fpage>&#x2013;<lpage>471</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2012.09.042</pub-id></citation></ref>
<ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname> <given-names>H. J.</given-names></name> <name><surname>Song</surname> <given-names>M. J.</given-names></name> <name><surname>Deng</surname> <given-names>H.</given-names></name> <name><surname>Wu</surname> <given-names>T. T.</given-names></name> <name><surname>Cheng</surname> <given-names>G.</given-names></name> <name><surname>Sun</surname> <given-names>R.</given-names></name></person-group> (<year>2003</year>). <article-title>NF-kappaB inhibits gammaherpesvirus lytic replication.</article-title> <source><italic>J. Virol.</italic></source> <volume>77</volume> <fpage>8532</fpage>&#x2013;<lpage>8540</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.77.15.8532-8540.2003</pub-id></citation></ref>
<ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cahir-McFarland</surname> <given-names>E. D.</given-names></name> <name><surname>Davidson</surname> <given-names>D. M.</given-names></name> <name><surname>Schauer</surname> <given-names>S. L.</given-names></name> <name><surname>Duong</surname> <given-names>J.</given-names></name> <name><surname>Kieff</surname> <given-names>E.</given-names></name></person-group> (<year>2000</year>). <article-title>NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>97</volume> <fpage>6055</fpage>&#x2013;<lpage>6060</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.100119497</pub-id></citation></ref>
<ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname> <given-names>E. M.</given-names></name> <name><surname>Weingart</surname> <given-names>J.</given-names></name> <name><surname>Sette</surname> <given-names>P.</given-names></name> <name><surname>Opp</surname> <given-names>S.</given-names></name> <name><surname>Sastri</surname> <given-names>J.</given-names></name> <name><surname>O&#x2019;Connor</surname> <given-names>S. K.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>TRIM5alpha-mediated ubiquitin chain conjugation is required for inhibition of HIV-1 reverse transcription and capsid destabilization.</article-title> <source><italic>J. Virol.</italic></source> <volume>90</volume> <fpage>1849</fpage>&#x2013;<lpage>1857</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01948-15</pub-id></citation></ref>
<ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname> <given-names>L. K.</given-names></name> <name><surname>Chuang</surname> <given-names>J. Y.</given-names></name> <name><surname>Nakao</surname> <given-names>M.</given-names></name> <name><surname>Liu</surname> <given-names>S. T.</given-names></name></person-group> (<year>2010</year>). <article-title>MCAF1 and synergistic activation of the transcription of Epstein-Barr virus lytic genes by Rta and Zta.</article-title> <source><italic>Nucleic Acids Res.</italic></source> <volume>38</volume> <fpage>4687</fpage>&#x2013;<lpage>4700</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkq243</pub-id></citation></ref>
<ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname> <given-names>L. K.</given-names></name> <name><surname>Chung</surname> <given-names>J. Y.</given-names></name> <name><surname>Hong</surname> <given-names>Y. R.</given-names></name> <name><surname>Ichimura</surname> <given-names>T.</given-names></name> <name><surname>Nakao</surname> <given-names>M.</given-names></name> <name><surname>Liu</surname> <given-names>S. T.</given-names></name></person-group> (<year>2005</year>). <article-title>Activation of Sp1-mediated transcription by Rta of Epstein-Barr virus via an interaction with MCAF1.</article-title> <source><italic>Nucleic Acids Res.</italic></source> <volume>33</volume> <fpage>6528</fpage>&#x2013;<lpage>6539</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gki956</pub-id></citation></ref>
<ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname> <given-names>L. K.</given-names></name> <name><surname>Lee</surname> <given-names>Y. H.</given-names></name> <name><surname>Cheng</surname> <given-names>T. S.</given-names></name> <name><surname>Hong</surname> <given-names>Y. R.</given-names></name> <name><surname>Lu</surname> <given-names>P. J.</given-names></name> <name><surname>Wang</surname> <given-names>J. J.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Post-translational modification of Rta of Epstein-Barr virus by SUMO-1.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>279</volume> <fpage>38803</fpage>&#x2013;<lpage>38812</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M405470200</pub-id></citation></ref>
<ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname> <given-names>L. K.</given-names></name> <name><surname>Liu</surname> <given-names>S. T.</given-names></name></person-group> (<year>2000</year>). <article-title>Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation.</article-title> <source><italic>Nucleic Acids Res.</italic></source> <volume>28</volume> <fpage>3918</fpage>&#x2013;<lpage>3925</lpage>. <pub-id pub-id-type="doi">10.1093/nar/28.20.3918</pub-id></citation></ref>
<ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname> <given-names>P. J.</given-names></name> <name><surname>Chang</surname> <given-names>Y. S.</given-names></name> <name><surname>Liu</surname> <given-names>S. T.</given-names></name></person-group> (<year>1998</year>). <article-title>Role of Rta in the translation of bicistronic BZLF1 of Epstein-Barr virus.</article-title> <source><italic>J. Virol.</italic></source> <volume>72</volume> <fpage>5128</fpage>&#x2013;<lpage>5136</lpage>.</citation></ref>
<ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname> <given-names>Y. F.</given-names></name> <name><surname>Tung</surname> <given-names>C. P.</given-names></name> <name><surname>Lee</surname> <given-names>Y. H.</given-names></name> <name><surname>Wang</surname> <given-names>W. H.</given-names></name> <name><surname>Li</surname> <given-names>C.</given-names></name> <name><surname>Hung</surname> <given-names>J. Y.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>A comprehensive library of mutations of Epstein Barr virus.</article-title> <source><italic>J. Gen. Virol.</italic></source> <volume>88</volume> <fpage>2463</fpage>&#x2013;<lpage>2472</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.82881-0</pub-id></citation></ref>
<ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname> <given-names>A. H.</given-names></name> <name><surname>Grand</surname> <given-names>R. J.</given-names></name> <name><surname>Evans</surname> <given-names>F. J.</given-names></name> <name><surname>Rickinson</surname> <given-names>A. B.</given-names></name></person-group> (<year>1991</year>). <article-title>Induction of Epstein-Barr virus lytic cycle by tumor-promoting and non-tumor-promoting phorbol esters requires active protein kinase C.</article-title> <source><italic>J. Virol.</italic></source> <volume>65</volume> <fpage>6838</fpage>&#x2013;<lpage>6844</lpage>.</citation></ref>
<ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diaz-Griffero</surname> <given-names>F.</given-names></name> <name><surname>Gallo</surname> <given-names>D. E.</given-names></name> <name><surname>Hope</surname> <given-names>T. J.</given-names></name> <name><surname>Sodroski</surname> <given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>Trafficking of some old world primate TRIM5alpha proteins through the nucleus.</article-title> <source><italic>Retrovirology</italic></source> <volume>8</volume>: <issue>38</issue>. <pub-id pub-id-type="doi">10.1186/1742-4690-8-38</pub-id></citation></ref>
<ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ganser-Pornillos</surname> <given-names>B. K.</given-names></name> <name><surname>Chandrasekaran</surname> <given-names>V.</given-names></name> <name><surname>Pornillos</surname> <given-names>O.</given-names></name> <name><surname>Sodroski</surname> <given-names>J. G.</given-names></name> <name><surname>Sundquist</surname> <given-names>W. I.</given-names></name> <name><surname>Yeager</surname> <given-names>M.</given-names></name></person-group> (<year>2011</year>). <article-title>Hexagonal assembly of a restricting TRIM5alpha protein.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>108</volume> <fpage>534</fpage>&#x2013;<lpage>539</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1013426108</pub-id></citation></ref>
<ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hatziioannou</surname> <given-names>T.</given-names></name> <name><surname>Perez-Caballero</surname> <given-names>D.</given-names></name> <name><surname>Yang</surname> <given-names>A.</given-names></name> <name><surname>Cowan</surname> <given-names>S.</given-names></name> <name><surname>Bieniasz</surname> <given-names>P. D.</given-names></name></person-group> (<year>2004</year>). <article-title>Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>101</volume> <fpage>10774</fpage>&#x2013;<lpage>10779</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0402361101</pub-id></citation></ref>
<ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heilmann</surname> <given-names>A. M.</given-names></name> <name><surname>Calderwood</surname> <given-names>M. A.</given-names></name> <name><surname>Johannsen</surname> <given-names>E.</given-names></name></person-group> (<year>2010</year>). <article-title>Epstein-Barr virus LF2 protein regulates viral replication by altering Rta subcellular localization.</article-title> <source><italic>J. Virol.</italic></source> <volume>84</volume> <fpage>9920</fpage>&#x2013;<lpage>9931</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00573-10</pub-id></citation></ref>
<ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hendriks</surname> <given-names>I. A.</given-names></name> <name><surname>Schimmel</surname> <given-names>J.</given-names></name> <name><surname>Eifler</surname> <given-names>K.</given-names></name> <name><surname>Olsen</surname> <given-names>J. V.</given-names></name> <name><surname>Vertegaal</surname> <given-names>A. C.</given-names></name></person-group> (<year>2015</year>). <article-title>Ubiquitin-specific protease 11 (USP11) deubiquitinates hybrid small ubiquitin-like modifier (SUMO)-ubiquitin chains to counteract RING Finger protein 4 (RNF4).</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>290</volume> <fpage>15526</fpage>&#x2013;<lpage>15537</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M114.618132</pub-id></citation></ref>
<ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname> <given-names>T. Y.</given-names></name> <name><surname>Chang</surname> <given-names>Y.</given-names></name> <name><surname>Wang</surname> <given-names>P. W.</given-names></name> <name><surname>Liu</surname> <given-names>M. Y.</given-names></name> <name><surname>Chen</surname> <given-names>M. R.</given-names></name> <name><surname>Chen</surname> <given-names>J. Y.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Reactivation of Epstein-Barr virus can be triggered by an Rta protein mutated at the nuclear localization signal.</article-title> <source><italic>J. Gen. Virol.</italic></source> <volume>86</volume> <fpage>317</fpage>&#x2013;<lpage>322</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.80556-0</pub-id></citation></ref>
<ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keckesova</surname> <given-names>Z.</given-names></name> <name><surname>Ylinen</surname> <given-names>L. M.</given-names></name> <name><surname>Towers</surname> <given-names>G. J.</given-names></name></person-group> (<year>2004</year>). <article-title>The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>101</volume> <fpage>10780</fpage>&#x2013;<lpage>10785</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0402474101</pub-id></citation></ref>
<ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>T. Y.</given-names></name> <name><surname>Chu</surname> <given-names>Y. Y.</given-names></name> <name><surname>Yang</surname> <given-names>Y. C.</given-names></name> <name><surname>Hsu</surname> <given-names>S. W.</given-names></name> <name><surname>Liu</surname> <given-names>S. T.</given-names></name> <name><surname>Chang</surname> <given-names>L. K.</given-names></name></person-group> (<year>2014</year>). <article-title>MCAF1 and Rta-activated BZLF1 transcription in Epstein-Barr virus.</article-title> <source><italic>PLoS ONE</italic></source> <volume>9</volume>: <issue>e90698</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0090698</pub-id></citation></ref>
<ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>P.</given-names></name> <name><surname>Speck</surname> <given-names>S. H.</given-names></name></person-group> (<year>2003</year>). <article-title>Synergistic autoactivation of the Epstein-Barr virus immediate-early BRLF1 promoter by Rta and Zta.</article-title> <source><italic>Virology</italic></source> <volume>310</volume> <fpage>199</fpage>&#x2013;<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1016/S0042-6822(03)00145-4</pub-id></citation></ref>
<ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luban</surname> <given-names>J.</given-names></name></person-group> (<year>2007</year>). <article-title>Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection.</article-title> <source><italic>J. Virol.</italic></source> <volume>81</volume> <fpage>1054</fpage>&#x2013;<lpage>1061</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01519-06</pub-id></citation></ref>
<ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luka</surname> <given-names>J.</given-names></name> <name><surname>Kallin</surname> <given-names>B.</given-names></name> <name><surname>Klein</surname> <given-names>G.</given-names></name></person-group> (<year>1979</year>). <article-title>Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate.</article-title> <source><italic>Virology</italic></source> <volume>94</volume> <fpage>228</fpage>&#x2013;<lpage>231</lpage>. <pub-id pub-id-type="doi">10.1016/0042-6822(79)90455-0</pub-id></citation></ref>
<ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perron</surname> <given-names>M. J.</given-names></name> <name><surname>Stremlau</surname> <given-names>M.</given-names></name> <name><surname>Song</surname> <given-names>B.</given-names></name> <name><surname>Ulm</surname> <given-names>W.</given-names></name> <name><surname>Mulligan</surname> <given-names>R. C.</given-names></name> <name><surname>Sodroski</surname> <given-names>J.</given-names></name></person-group> (<year>2004</year>). <article-title>TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>101</volume> <fpage>11827</fpage>&#x2013;<lpage>11832</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0403364101</pub-id></citation></ref>
<ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pertel</surname> <given-names>T.</given-names></name> <name><surname>Hausmann</surname> <given-names>S.</given-names></name> <name><surname>Morger</surname> <given-names>D.</given-names></name> <name><surname>Zuger</surname> <given-names>S.</given-names></name> <name><surname>Guerra</surname> <given-names>J.</given-names></name> <name><surname>Lascano</surname> <given-names>J.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>TRIM5 is an innate immune sensor for the retrovirus capsid lattice.</article-title> <source><italic>Nature</italic></source> <volume>472</volume> <fpage>361</fpage>&#x2013;<lpage>365</lpage>. <pub-id pub-id-type="doi">10.1038/nature09976</pub-id></citation></ref>
<ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reszka</surname> <given-names>N.</given-names></name> <name><surname>Zhou</surname> <given-names>C.</given-names></name> <name><surname>Song</surname> <given-names>B.</given-names></name> <name><surname>Sodroski</surname> <given-names>J. G.</given-names></name> <name><surname>Knipe</surname> <given-names>D. M.</given-names></name></person-group> (<year>2010</year>). <article-title>Simian TRIM5alpha proteins reduce replication of herpes simplex virus.</article-title> <source><italic>Virology</italic></source> <volume>398</volume> <fpage>243</fpage>&#x2013;<lpage>250</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2009.11.041</pub-id></citation></ref>
<ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reymond</surname> <given-names>A.</given-names></name> <name><surname>Meroni</surname> <given-names>G.</given-names></name> <name><surname>Fantozzi</surname> <given-names>A.</given-names></name> <name><surname>Merla</surname> <given-names>G.</given-names></name> <name><surname>Cairo</surname> <given-names>S.</given-names></name> <name><surname>Luzi</surname> <given-names>L.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>The tripartite motif family identifies cell compartments.</article-title> <source><italic>EMBO J.</italic></source> <volume>20</volume> <fpage>2140</fpage>&#x2013;<lpage>2151</lpage>. <pub-id pub-id-type="doi">10.1093/emboj/20.9.2140</pub-id></citation></ref>
<ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname> <given-names>J. L.</given-names></name> <name><surname>Fan</surname> <given-names>H.</given-names></name> <name><surname>Glaser</surname> <given-names>S. L.</given-names></name> <name><surname>Schichman</surname> <given-names>S. A.</given-names></name> <name><surname>Raab-Traub</surname> <given-names>N.</given-names></name> <name><surname>Gulley</surname> <given-names>M. L.</given-names></name></person-group> (<year>2004</year>). <article-title>Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma.</article-title> <source><italic>J. Mol. Diagn.</italic></source> <volume>6</volume> <fpage>378</fpage>&#x2013;<lpage>385</lpage>. <pub-id pub-id-type="doi">10.1016/S1525-1578(10)60535-1</pub-id></citation></ref>
<ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sawyer</surname> <given-names>S. L.</given-names></name> <name><surname>Wu</surname> <given-names>L. I.</given-names></name> <name><surname>Emerman</surname> <given-names>M.</given-names></name> <name><surname>Malik</surname> <given-names>H. S.</given-names></name></person-group> (<year>2005</year>). <article-title>Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>102</volume> <fpage>2832</fpage>&#x2013;<lpage>2837</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0409853102</pub-id></citation></ref>
<ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schlieker</surname> <given-names>C.</given-names></name> <name><surname>Korbel</surname> <given-names>G. A.</given-names></name> <name><surname>Kattenhorn</surname> <given-names>L. M.</given-names></name> <name><surname>Ploegh</surname> <given-names>H. L.</given-names></name></person-group> (<year>2005</year>). <article-title>A deubiquitinating activity is conserved in the large tegument protein of the herpesviridae.</article-title> <source><italic>J. Virol.</italic></source> <volume>79</volume> <fpage>15582</fpage>&#x2013;<lpage>15585</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.79.24.15582-15585.2005</pub-id></citation></ref>
<ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shevchenko</surname> <given-names>A.</given-names></name> <name><surname>Wilm</surname> <given-names>M.</given-names></name> <name><surname>Vorm</surname> <given-names>O.</given-names></name> <name><surname>Mann</surname> <given-names>M.</given-names></name></person-group> (<year>1996</year>). <article-title>Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels.</article-title> <source><italic>Anal. Chem.</italic></source> <volume>68</volume> <fpage>850</fpage>&#x2013;<lpage>858</lpage>. <pub-id pub-id-type="doi">10.1021/ac950914h</pub-id></citation></ref>
<ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sompallae</surname> <given-names>R.</given-names></name> <name><surname>Gastaldello</surname> <given-names>S.</given-names></name> <name><surname>Hildebrand</surname> <given-names>S.</given-names></name> <name><surname>Zinin</surname> <given-names>N.</given-names></name> <name><surname>Hassink</surname> <given-names>G.</given-names></name> <name><surname>Lindsten</surname> <given-names>K.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Epstein-Barr virus encodes three bona fide ubiquitin-specific proteases.</article-title> <source><italic>J. Virol.</italic></source> <volume>82</volume> <fpage>10477</fpage>&#x2013;<lpage>10486</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01113-08</pub-id></citation></ref>
<ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Speck</surname> <given-names>S. H.</given-names></name> <name><surname>Chatila</surname> <given-names>T.</given-names></name> <name><surname>Flemington</surname> <given-names>E.</given-names></name></person-group> (<year>1997</year>). <article-title>Reactivation of Epstein-Barr virus: regulation and function of the BZLF1 gene.</article-title> <source><italic>Trends Microbiol.</italic></source> <volume>5</volume> <fpage>399</fpage>&#x2013;<lpage>405</lpage>. <pub-id pub-id-type="doi">10.1016/S0966-842X(97)01129-3</pub-id></citation></ref>
<ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stremlau</surname> <given-names>M.</given-names></name> <name><surname>Owens</surname> <given-names>C. M.</given-names></name> <name><surname>Perron</surname> <given-names>M. J.</given-names></name> <name><surname>Kiessling</surname> <given-names>M.</given-names></name> <name><surname>Autissier</surname> <given-names>P.</given-names></name> <name><surname>Sodroski</surname> <given-names>J.</given-names></name></person-group> (<year>2004</year>). <article-title>The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in old world monkeys.</article-title> <source><italic>Nature</italic></source> <volume>427</volume> <fpage>848</fpage>&#x2013;<lpage>853</lpage>. <pub-id pub-id-type="doi">10.1038/nature02343</pub-id></citation></ref>
<ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stremlau</surname> <given-names>M.</given-names></name> <name><surname>Perron</surname> <given-names>M.</given-names></name> <name><surname>Welikala</surname> <given-names>S.</given-names></name> <name><surname>Sodroski</surname> <given-names>J.</given-names></name></person-group> (<year>2005</year>). <article-title>Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction.</article-title> <source><italic>J. Virol.</italic></source> <volume>79</volume> <fpage>3139</fpage>&#x2013;<lpage>3145</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.79.5.3139-3145.2005</pub-id></citation></ref>
<ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Terrin</surname> <given-names>L.</given-names></name> <name><surname>Dolcetti</surname> <given-names>R.</given-names></name> <name><surname>Corradini</surname> <given-names>I.</given-names></name> <name><surname>Indraccolo</surname> <given-names>S.</given-names></name> <name><surname>Dal Col</surname> <given-names>J.</given-names></name> <name><surname>Bertorelle</surname> <given-names>R.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: implications for EBV-driven lymphomagenesis.</article-title> <source><italic>Int. J. Cancer</italic></source> <volume>121</volume> <fpage>576</fpage>&#x2013;<lpage>587</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.22661</pub-id></citation></ref>
<ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>W. H.</given-names></name> <name><surname>Kuo</surname> <given-names>C. W.</given-names></name> <name><surname>Chang</surname> <given-names>L. K.</given-names></name> <name><surname>Hung</surname> <given-names>C. C.</given-names></name> <name><surname>Chang</surname> <given-names>T. H.</given-names></name> <name><surname>Liu</surname> <given-names>S. T.</given-names></name></person-group> (<year>2015</year>). <article-title>Assembly of Epstein-Barr virus capsid in promyelocytic leukemia nuclear bodies.</article-title> <source><italic>J. Virol.</italic></source> <volume>89</volume> <fpage>8922</fpage>&#x2013;<lpage>8931</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01114-15</pub-id></citation></ref>
<ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>C. Y.</given-names></name> <name><surname>Chen</surname> <given-names>C. L.</given-names></name> <name><surname>Lee</surname> <given-names>Y. H.</given-names></name> <name><surname>Cheng</surname> <given-names>Y. C.</given-names></name> <name><surname>Wu</surname> <given-names>Y. C.</given-names></name> <name><surname>Shu</surname> <given-names>H. Y.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Nonribosomal synthesis of fengycin on an enzyme complex formed by fengycin synthetases.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>282</volume> <fpage>5608</fpage>&#x2013;<lpage>5616</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M609726200</pub-id></citation></ref>
<ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamauchi</surname> <given-names>K.</given-names></name> <name><surname>Wada</surname> <given-names>K.</given-names></name> <name><surname>Tanji</surname> <given-names>K.</given-names></name> <name><surname>Tanaka</surname> <given-names>M.</given-names></name> <name><surname>Kamitani</surname> <given-names>T.</given-names></name></person-group> (<year>2008</year>). <article-title>Ubiquitination of E3 ubiquitin ligase TRIM5 alpha and its potential role.</article-title> <source><italic>FEBS J.</italic></source> <volume>275</volume> <fpage>1540</fpage>&#x2013;<lpage>1555</lpage>. <pub-id pub-id-type="doi">10.1111/j.1742-4658.2008.06313.x</pub-id></citation></ref>
<ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>Y. C.</given-names></name> <name><surname>Chang</surname> <given-names>L. K.</given-names></name></person-group> (<year>2013</year>). <article-title>Role of TAF4 in transcriptional activation by Rta of Epstein-Barr Virus.</article-title> <source><italic>PLoS ONE</italic></source> <volume>8</volume>: <issue>e54075</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0054075</pub-id></citation></ref>
<ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>Y. C.</given-names></name> <name><surname>Yoshikai</surname> <given-names>Y.</given-names></name> <name><surname>Hsu</surname> <given-names>S. W.</given-names></name> <name><surname>Saitoh</surname> <given-names>H.</given-names></name> <name><surname>Chang</surname> <given-names>L. K.</given-names></name></person-group> (<year>2013</year>). <article-title>Role of RNF4 in the ubiquitination of Rta of Epstein-Barr virus.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>288</volume> <fpage>12866</fpage>&#x2013;<lpage>12879</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M112.413393</pub-id></citation></ref>
<ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yap</surname> <given-names>M. W.</given-names></name> <name><surname>Nisole</surname> <given-names>S.</given-names></name> <name><surname>Lynch</surname> <given-names>C.</given-names></name> <name><surname>Stoye</surname> <given-names>J. P.</given-names></name></person-group> (<year>2004</year>). <article-title>Trim5alpha protein restricts both HIV-1 and murine leukemia virus.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>101</volume> <fpage>10786</fpage>&#x2013;<lpage>10791</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0402876101</pub-id></citation></ref>
<ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zalani</surname> <given-names>S.</given-names></name> <name><surname>Coppage</surname> <given-names>A.</given-names></name> <name><surname>Holley-Guthrie</surname> <given-names>E.</given-names></name> <name><surname>Kenney</surname> <given-names>S.</given-names></name></person-group> (<year>1997</year>). <article-title>The cellular YY1 transcription factor binds a cis-acting, negatively regulating element in the Epstein-Barr virus BRLF1 promoter.</article-title> <source><italic>J. Virol.</italic></source> <volume>71</volume> <fpage>3268</fpage>&#x2013;<lpage>3274</lpage>.</citation></ref>
<ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zalani</surname> <given-names>S.</given-names></name> <name><surname>Holley-Guthrie</surname> <given-names>E. A.</given-names></name> <name><surname>Gutsch</surname> <given-names>D. E.</given-names></name> <name><surname>Kenney</surname> <given-names>S. C.</given-names></name></person-group> (<year>1992</year>). <article-title>The Epstein-Barr virus immediate-early promoter BRLF1 can be activated by the cellular Sp1 transcription factor.</article-title> <source><italic>J. Virol.</italic></source> <volume>66</volume> <fpage>7282</fpage>&#x2013;<lpage>7292</lpage>.</citation></ref>
</ref-list>
<fn-group>
<fn id="fn01"><label>1</label><p><ext-link ext-link-type="uri" xlink:href="http://rnai.genmed.sinica.edu.tw/webContent/web/protocols">http://rnai.genmed.sinica.edu.tw/webContent/web/protocols</ext-link></p></fn>
</fn-group>
</back>
</article>